Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05826457 · ClinicalTrials.gov registry record
North American Prodromal Synucleinopathy Consortium Stage 2
A clinical trial of Parkinson Disease and Multiple System Atrophy, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 500
- Enrollment target
- 9
- Study locations
NCT05826457: Recruiting study of Parkinson Disease and Multiple System Atrophy, sponsored by Washington University School of Medicine.
NCT05826457 is a study of Parkinson Disease and Multiple System Atrophy that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 500 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05826457, a study of Parkinson Disease and Multiple System Atrophy, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Conditions Studied
Study Locations (9)
California
- University of California Los Angeles - Los Angeles
- Stanford University - Redwood City
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic Rochester - Rochester
Georgia
- Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
Oregon
- Oregon Health Sciences University - Portland
Quebec
- McGill University Health Centre Research Institute - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2025-05-01 |
What NCT05826457 shows while recruiting
NCT05826457 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (91% lower).
The record links to 6 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05826457 lists 9 locations in 7 states (California, Minnesota, Georgia).
Frequently Asked Questions
What is clinical trial NCT05826457 about?
NCT05826457 is a clinical study titled "North American Prodromal Synucleinopathy Consortium Stage 2". This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
What is the current status of trial NCT05826457?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-08-12. Estimated completion is 2025-05-01.
What conditions does trial NCT05826457 study?
This clinical trial studies the following conditions: Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Lewy Body Dementia.
Who is sponsoring clinical trial NCT05826457?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05826457 being conducted?
This trial has 9 study locations across California, Georgia, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05826457's enrollment target sits among peer trials
500 23rd of 297 higher than 274 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI